Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Nephros (NEPH) Amortization - Deferred Charges (2011 - 2014)

Nephros' quarterly Amortization - Deferred Charges came in at $142000.0 in Q1 2014, down 30.39% year-on-year from $204000.0 in Q1 2013, and down 30.39% quarter-over-quarter from $204000.0 in Q1 2013.

Nephros has reported Amortization - Deferred Charges for 3 years, with the latest figure at $142000.0 in Q1 2014.

  • For the quarter ending Q1 2014, Amortization - Deferred Charges fell 30.39% year-over-year to $142000.0; the trailing twelve-month figure through Mar 2014 stood at $346000.0 (up 69.61% YoY), and the FY2013 full-year result was $257000.0, changed N/A from the prior year.
  • Amortization - Deferred Charges for Q1 2014 stood at $142000.0, down from $204000.0 in the prior quarter.
  • The five-year high for Amortization - Deferred Charges was $204000.0 in Q1 2013, with the low at $40000.0 in Q1 2011.
  • Average Amortization - Deferred Charges over 3 years is $128666.7, with a median of $142000.0 recorded in 2014.
  • Peak annual rise in Amortization - Deferred Charges reached 30.39% in 2014, while the deepest fall reached 30.39% in 2014.
  • Tracing NEPH's Amortization - Deferred Charges over 3 years: stood at $40000.0 in 2011, then soared by 410.0% to $204000.0 in 2013, then plunged by 30.39% to $142000.0 in 2014.
  • The last three Amortization - Deferred Charges figures came in at $142000.0 (Q1 2014), $204000.0 (Q1 2013), and $40000.0 (Q1 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortization - Deferred Charges (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn -
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn -
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn -
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn -
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn -
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn -
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn -
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn -
10 Nephros 38.93 Mn 34.91 Mn 2.99 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 142,000.00
Mar 31, 2014 142,000.00
Mar 31, 2013 204,000.00
Mar 31, 2013 204,000.00
Mar 31, 2011 40,000.00
Mar 31, 2011 40,000.00